Aerocrine and Panasonic Shikoku Electronics enter into asthma partnership

Aerocrine and Panasonic Shikoku Electronics enter into asthma partnership

SOLNA, Sweden - 4 November 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) today
announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have
entered into a long-term agreement to develop, manufacture and market new
generation products for airway inflammation monitoring using exhaled nitric
oxide. 

PSEC, a wholly owned subsidiary of Panasonic Corporation, is a world class
electronic development, manufacturing and marketing corporation with extensive
experience in designing and manufacturing consumer and professional medical
devices. Aerocrine is a clinically based medical technology corporation that
discovered exhaled nitric oxide monitoring for clinical use in asthma care and
leads the market with proprietary technology and products for airway
inflammation measurement. 

Under the agreement, Aerocrine and PSEC will collaborate to develop future
generations of products for airway inflammation monitoring for both clinical and
personal use. PSEC will be responsible for the worldwide manufacture and supply
of the products and Aerocrine will be responsible for regulatory approvals,
method development and global commercialization.

”PSEC has identified airway inflammation monitoring using exhaled nitric oxide
as a very significant growth opportunity both for clinical use and for use by
patients in the home”, says Kazuya Nakaya, Managing Director and Member of the
Board of PSEC. ”Aerocrine is the global market leader with strong intellectual
property and know-how and we look forward to working together.” 

”The market for airway inflammation monitoring in clinical practice is
developing rapidly. To maintain our position as market leaders and continue to
lead the technical development for growing applications and new customer groups,
we will benefit from working with a strong partner”, says Paul de Potocki, CEO
of Aerocrine AB. ”For us, PSEC is the ideal partner with its wide technical
expertise and successful history of medical device manufacturing.”

Asthma is one of the world's most widespread diseases, affecting around 300
million people. Measurements of exhaled nitric oxide, eNO, can help to identify
ongoing airway inflammation in asthma patients with or without symptoms in order
to help ensure a more accurate diagnosis, predict and measure response to
anti-inflammatory medication and help clinicians to make more informed treatment
decisions. In treatment follow-up, eNO measurements can help detect poor
anti-inflammatory medication adherence and delivery problems, as well as
allergen exposure. 

Many believe that eNO monitoring will develop into an application for home use.
The home monitoring model has worked successfully in the management of other
chronic diseases that achieve control through optimized drug delivery. Blood
glucose meters, for example, have enabled patients with diabetes to personalize
their treatment and proactively manage their disease at home. Airway
inflammation meters have the potential to help move asthma therapy from symptom
response to proactive, personalized and cost-effective disease management.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80

About Panasonic Shikoku Electronics
Panasonic Shikoku Electronics Co., Ltd., headquartered in Matsuyama, Japan, is a
Panasonic Group company specialized in the development and manufacture of
healthcare products such as blood glucose monitoring systems, ultrasound
diagnostic systems, hearing aids and injection ampoule dispensing robot systems.
Founded in 1948, the company has been developing cutting edge technologies in
in-vitro diagnostic systems, medical imaging, hearing solutions and hospital
systems to provide value-added solutions to healthcare professionals and
patients.  
For more information, visit the company web site at
http://panasonic.net/corporate/segments/psec/ .

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO® and NIOX® Flex. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
08:00 am on November the 4th 2009.